Barclays Issues Positive Forecast for Hims & Hers Health (NYSE:HIMS) Stock Price

Hims & Hers Health (NYSE:HIMS) had its price target boosted by Barclays from $25.00 to $29.00 in a research note published on Wednesday,Benzinga reports. The firm currently has an overweight rating on the stock.

Several other research firms have also commented on HIMS. Leerink Partners cut their price objective on Hims & Hers Health from $20.00 to $17.50 and set a “market perform” rating for the company in a research note on Tuesday, February 24th. Deutsche Bank Aktiengesellschaft lifted their price target on Hims & Hers Health from $25.00 to $28.00 and gave the stock a “hold” rating in a research note on Tuesday. TD Cowen reduced their price objective on Hims & Hers Health from $20.00 to $17.00 and set a “hold” rating for the company in a research note on Tuesday, February 24th. Evercore set a $24.00 price objective on Hims & Hers Health in a report on Tuesday, February 24th. Finally, Morgan Stanley lowered their target price on shares of Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 24th. Three analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and a consensus target price of $30.75.

Hims & Hers Health Stock Up 10.3%

Shares of NYSE HIMS opened at $25.89 on Wednesday. The company’s 50-day simple moving average is $24.18 and its 200-day simple moving average is $37.66. Hims & Hers Health has a 52-week low of $13.74 and a 52-week high of $70.43. The firm has a market cap of $5.90 billion, a price-to-earnings ratio of 50.76, a price-to-earnings-growth ratio of 4.55 and a beta of 2.55. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.06. The business had revenue of $617.82 million during the quarter, compared to analysts’ expectations of $619.48 million. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The company’s quarterly revenue was up 28.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.11 earnings per share. Equities analysts predict that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Hims & Hers Health announced that its Board of Directors has initiated a share repurchase program on Monday, November 17th that allows the company to buyback $250.00 million in shares. This buyback authorization allows the company to purchase up to 3% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s management believes its shares are undervalued.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 9,067 shares of the company’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $30.34, for a total value of $275,092.78. Following the transaction, the chief financial officer owned 91,617 shares of the company’s stock, valued at $2,779,659.78. This represents a 9.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Patrick Harrison Carroll sold 10,021 shares of the stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $367,870.91. Following the transaction, the insider directly owned 169,940 shares of the company’s stock, valued at approximately $6,238,497.40. This trade represents a 5.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 80,463 shares of company stock worth $2,846,696 in the last 90 days. Insiders own 13.71% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds have recently made changes to their positions in HIMS. Pathway Capital Management LP acquired a new stake in shares of Hims & Hers Health in the third quarter valued at $6,766,000. Steadview Capital Management LLC lifted its stake in Hims & Hers Health by 80.0% during the 3rd quarter. Steadview Capital Management LLC now owns 701,845 shares of the company’s stock worth $39,809,000 after acquiring an additional 311,845 shares in the last quarter. State of Michigan Retirement System boosted its holdings in Hims & Hers Health by 49.2% during the 3rd quarter. State of Michigan Retirement System now owns 2,057,700 shares of the company’s stock valued at $116,713,000 after acquiring an additional 678,600 shares during the period. Carnegie Investment Counsel boosted its holdings in Hims & Hers Health by 25.4% during the 3rd quarter. Carnegie Investment Counsel now owns 303,909 shares of the company’s stock valued at $17,238,000 after acquiring an additional 61,560 shares during the period. Finally, BIT Capital GmbH grew its position in Hims & Hers Health by 73.8% in the 3rd quarter. BIT Capital GmbH now owns 2,210,384 shares of the company’s stock valued at $125,373,000 after acquiring an additional 938,728 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Landmark Novo Nordisk partnership — the deal replaces compounded GLP‑1 sales with distribution of branded Wegovy/Ozempic (including new pill forms), materially reducing legal risk and legitimizing HIMS’ platform; analysts and market commentary see this as transformational for revenue and margins. Read More. Read More.
• Positive Sentiment: Analyst upgrades and higher price targets — multiple firms (Barclays, Needham, Deutsche Bank and others) have raised ratings/targets after the Novo news, supporting upside and prompting fresh buy interest. Read More. Read More.
• Positive Sentiment: Large call‑option activity — unusually heavy call buying (322k calls, ~128% above normal) signals speculative and directional bullish positioning that can amplify intraday moves and volatility. Read More.
• Neutral Sentiment: Strong 2025 operating results provide context — HIMS reported $2.35B revenue (+59% YoY), solid EBITDA and cash flow, and 2.5M+ subscribers with improving ARPU/cross‑sell metrics, which support a longer‑term bull case but leave execution risk. Read More.
• Neutral Sentiment: Corporate hire and platform expansion — appointment of a new Chief Communications Officer and product/platform expansions are governance/brand positives but are longer‑dated catalysts. Read More.
• Neutral Sentiment: Mixed brokerage consensus — while a number of firms upgraded, the street average rating remains around “Hold,” so fresh positive headlines may be needed to sustain multiple expansion. Read More.
• Negative Sentiment: Some institutional selling noted — at least one asset manager trimmed/exit positions despite the deal; this could add supply and headwinds if other holders follow. Read More.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.